Kidney disease focus Target opportunities around nephrology-focused partnerships and services, emphasizing Akebia's core mission to develop therapeutics for kidney disease to align with potential CROs, contract manufacturing, and academic collaborations seeking kidney disease programs.

Pipeline expansion Leverage Akebia's ongoing kidney disease pipeline including praliciguat, AKB-097, and AKB-9090 to identify potential licensing, co-development, or milestone-based collaborations with biotech firms and research institutions seeking to expand their nephrology portfolios.

Strategic acquisitions Position for inorganic growth discussions in light of recent asset acquisitions such as ebribafusp rights from Q32 Bio, exploring partnerships or asset swaps with companies looking to optimize their kidney disease assets or portfolio diversification.

Expansion footprint Capitalize on plans to establish a larger headquarters in Waltham and expand operations to enhance regional presence; pursue local vendors, facilities contracts, and regional clinical trial sites or vendor partnerships to support scale and speed to market.

Financial readiness Align outreach with Akebia's solid funding base and mid-range revenue, targeting strategic investors, CROs, and service providers that can support scale in trials and commercialization, including potential collaborations around cost-sharing or revenue milestones.